Abstract:Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the potential of LB100, a small-molecule protein phosphatase 2 A (PP2A) inhibitor, as a monotherapy and chemosensitizing agent for sAML using an in-vitro and in-vivo approach. We demonstrate that LB100 decreases cell viability through caspase activation and G2/M cell-cycle arrest. LB100 enhances daunorubicin (DNR) cytotoxicity resulting in decreased xenograft volumes and improved overall survival. LB100 profoundly upregulates miR-181b-1, which we show directly binds to the 3′ untranslated region of Bcl-2 mRNA leading to its translational inhibition. MiR-181b-1 ectopic overexpression further diminishes Bcl-2 expression leading to suppression of sAML cell growth, and enhancement of DNR cytotoxicity. Our research highlights the therapeutic potential of LB100, and provides new insights into the mechanism of LB100 chemosensitization.

Pp2a Inhibition From Lb100 Therapy Enhances Daunorubicin Cytotoxicity In Secondary Acute Myeloid Leukemia Via Mir-181b-1 Upregulation (Vol 7, 2894, 2017)

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Mir-148b Suppresses Cell Proliferation And Invasion In Hepatocellular Carcinoma By Targeting Wnt1/Beta-Catenin Pathway (Vol 5, 8087, 2015)

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing Mir-145/Smad3 Signaling

Correction To: Exosome-transmitted Mir-128-3p Increase Chemosensitivity of Oxaliplatin-Resistant Colorectal Cancer

Involvement of Mir-125A in Resistance to Daunorubicin by Inhibiting Apoptosis in Leukemia Cell Lines

Supplementary Figure 8 from Inhibition of Mir-17 and Mir-20A by Oridonin Triggers Apoptosis and Reverses Chemoresistance by Derepressing BIM-S

Correction: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer

Involvement of Mir-21 in Resistance to Daunorubicin by Regulating PTEN Expression in the Leukaemia K562 Cell Line

Author Correction: TGF-β1-induced Mir-503 Controls Cell Growth and Apoptosis by Targeting PDCD4 in Glioblastoma Cells

Author Correction: Genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with concurrent chemoradiotherapy toxicities and efficacy in nasopharyngeal carcinoma patients

Correction: Publisher Correction: Simultaneous Overactivation of Wnt/β-catenin and TGFβ Signalling by Mir-128-3p Confers Chemoresistance-Associated Metastasis in NSCLC

Erratum: Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Supplementary Figure 6 from Inhibition of Mir-17 and Mir-20A by Oridonin Triggers Apoptosis and Reverses Chemoresistance by Derepressing BIM-S

Correction: Corrigendum: Doxorubicin-loaded Platelets As a Smart Drug Delivery System: an Improved Therapy for Lymphoma

Correction: Multivalent Presentation of MPL by Porous Silicon Microparticles Favors T Helper 1 Polarization Enhancing the Anti-Tumor Efficacy of Doxorubicin Nanoliposomes.